How should caplacizumab be used for treatment of immune thrombotic thrombocytopenic purpura?

被引：0
|
作者：
Zheng, Lucy [1 ]
Zheng, X. Long [1 ]
机构：
[1] Univ Kansas, Med Ctr, Dept Pathol & Lab Med, 3901 Rainbow Blvd,Delp 5016, Kansas City, KS 66160 USA
来源：
ANNALS OF BLOOD | 2023年 / 8卷
关键词：
PLASMA-EXCHANGE; REFRACTORINESS; MORTALITY; ADAMTS13;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Initial US tertiary health care system experience using caplacizumab in patients with immune thrombotic thrombocytopenic purpura
    Jones, Jennifer M.
    Kaplan, Alesia
    Chibisov, Irina
    Then, Janine
    Novelli, Enrico M.
    Kiss, Joseph E.
    ANNALS OF HEMATOLOGY, 2024, 103 (11) : 4449 - 4457
  • [22] Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura
    Hollifield, Alyssa L.
    Arnall, Justin R.
    Moore, Donald C.
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2020, 77 (15) : 1201 - 1207
  • [23] Cost analysis of the impact of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura from a US hospital perspective
    Pollissard, Laurence
    Leinwand, Brian, I
    Fournier, Marie
    Pham, Huy P.
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1178 - 1184
  • [24] Clinical Efficacy and Safety Profile of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura
    Maqsood, Muhammad Haisum
    Rubab, Kinza
    Maqsood, Muhammad Zaigham
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2019, 11 (07)
  • [25] Efficacy and safety of caplacizumab in the treatment of thrombotic thrombocytopenic purpura: a systematic review and meta-analysis
    He, Jingyi
    Qi, Jiaqian
    Han, Haohao
    Xu, Xiaoyan
    Li, Xueqian
    Song, Xiaofei
    Han, Yue
    EXPERT REVIEW OF HEMATOLOGY, 2023, 16 (05) : 377 - 385
  • [26] Do patients with immune-mediated thrombotic thrombocytopenic purpura receiving caplacizumab need antithrombotic therapy?
    Elverdi, Tugrul
    Ozer Cerme, Melis Dila
    Aydin, Tahacan
    Eskazan, Ahmet Emre
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2021, 14 (10) : 1183 - 1188
  • [27] Five years of caplacizumab - lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura
    Voelker, Linus Alexander
    Brinkkoetter, Paul Thomas
    Cataland, Spero R.
    Masias, Camila
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2023, 21 (10) : 2718 - 2725
  • [28] Treatment of acquired thrombotic thrombocytopenic purpura without plasma exchange in selected patients under caplacizumab
    Voelker, Linus A.
    Brinkkoetter, Paul T.
    Knoebl, Paul N.
    Krstic, Miroslav
    Kaufeld, Jessica
    Menne, Jan
    Buxhofer-Ausch, Veronika
    Miesbach, Wolfgang
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (11) : 3061 - 3066
  • [29] Treatment of thrombotic thrombocytopenic purpura
    Galstyan, Gennadii M.
    Maschan, Alexei A.
    Klebanova, Elizaveta E.
    Kalinina, Irina I.
    TERAPEVTICHESKII ARKHIV, 2021, 93 (07) : 826 - 829
  • [30] Treatment of thrombotic thrombocytopenic purpura
    Fontana, S
    Hovinga, JAK
    Lämmle, B
    Taleghani, BM
    VOX SANGUINIS, 2006, 90 (04) : 245 - 254
12345